Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jie Wen Gao | F | 44 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 3 jaar |
Sau Shan Ku | M | 55 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 2 jaar |
Dong Zhang | M | 48 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 2 jaar |
Jiang Tao Yu | M | 49 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 3 jaar |
Maio Li Pan | F | 47 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 2 jaar |
Wei Wang | M | 52 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Lai Wei | M | 47 |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | - |
Ming Jin | M | - |
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
China | 8 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Xue Bin Liu
- Persoonlijk netwerk